https://www.selleckchem.com/pr....oducts/3,4-dichlorop
Background Although combination therapy with immune checkpoint inhibitors (ICIs) provides a promising efficacy in multiple cancers, their use is facing challenges for a high incidence of adverse effects. This meta-analysis was conducted to compare the risks of organ-specific immune-related adverse events (IRAEs) associated with ICI monotherapy versus combination therapy among cancer patients. Methods Electronic databases were systematically searched to include eligible randomized controlled trials (RCTs). Any-g
Like
Comment
Share
